博雅生物
(300294)
| 流通市值：138.82亿 | | | 总市值：138.82亿 |
| 流通股本：5.04亿 | | | 总股本：5.04亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,299,851,770.61 | 1,988,439,866.94 | 3,252,295,313.33 | 1,860,435,345.29 |
| 应收票据及应收账款 | 453,404,517.85 | 303,485,433.15 | 322,238,104.66 | 240,863,138.38 |
| 其中：应收票据 | 4,933,656.1 | 10,376,443.2 | 2,602,850.2 | - |
| 应收账款 | 448,470,861.75 | 293,108,989.95 | 319,635,254.46 | 240,863,138.38 |
| 应收款项融资 | 55,974,878.8 | 51,790,707.66 | 58,458,577.06 | 77,354,865.01 |
| 预付款项 | 13,623,534.65 | 12,230,437.23 | 2,978,049.05 | 2,621,056.4 |
| 其他应收款合计 | 39,809,915 | 352,990,618.18 | 191,112,959.64 | 154,410,294.22 |
| 存货 | 995,427,153.22 | 627,577,385.11 | 577,321,177.61 | 566,513,200.98 |
| 其他流动资产 | 1,131,298.76 | 1,334,870.19 | 320,582.95 | 2,610,401.63 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 5,058,350,132.04 | 6,588,378,918.74 | 6,646,803,608.81 | 6,612,770,411.54 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 81,094,746.4 | 93,957,789.71 | 91,000,789.71 | 92,371,689.71 |
| 投资性房地产 | 598,669.62 | 611,250.96 | 623,832.3 | 636,418.7 |
| 固定资产 | 837,410,357.02 | 598,178,253.88 | 607,704,505.11 | 619,746,404.43 |
| 在建工程 | 321,002,761.13 | 191,617,028.92 | 55,267,341.02 | 40,975,483.83 |
| 使用权资产 | 11,789,360.01 | 5,165,257.35 | 5,717,169.67 | 2,039,060.2 |
| 无形资产 | 773,275,862.44 | 263,140,735.62 | 267,210,431.79 | 265,805,718.83 |
| 开发支出 | 108,443,041.47 | 64,765,178.98 | 61,187,087.44 | 55,927,561.91 |
| 商誉 | 727,996,027.69 | 72,612,799.46 | 72,612,799.46 | 72,612,799.46 |
| 长期待摊费用 | 37,452,984.7 | 42,300,179.5 | 31,319,331.59 | 33,009,917.33 |
| 递延所得税资产 | 73,537,423.69 | 44,955,211.52 | 50,087,609.12 | 50,008,208.14 |
| 其他非流动资产 | 370,193,402.78 | 192,264,854.07 | 133,811,234.96 | 146,946,796.8 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,342,794,636.95 | 1,569,568,539.97 | 1,376,542,132.17 | 1,380,080,059.34 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 8,401,144,768.99 | 8,157,947,458.71 | 8,023,345,740.98 | 7,992,850,470.88 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 357,623,076.65 | 219,866,525.88 | 138,486,278.07 | 115,834,621.51 |
| 其中：应付票据 | 207,704,840.99 | 145,394,474.86 | 67,730,569.57 | 48,194,526.67 |
| 应付账款 | 149,918,235.66 | 74,472,051.02 | 70,755,708.5 | 67,640,094.84 |
| 合同负债 | 4,076,548.97 | 4,027,787 | 5,794,636.5 | 8,145,843.27 |
| 应付职工薪酬 | 98,581,246.52 | 89,753,433.95 | 75,401,301.18 | 63,674,500.42 |
| 应交税费 | 27,965,410.99 | 22,192,572.12 | 41,022,703.07 | 41,426,245.67 |
| 其他应付款合计 | 256,128,209.46 | 209,722,807.15 | 223,606,171.29 | 238,762,851.41 |
| 一年内到期的非流动负债 | 5,333,163.12 | 2,086,814.55 | 22,961,005.13 | 871,310.68 |
| 其他流动负债 | 668,267.7 | 922,789.51 | 980,587.31 | 992,101.63 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 750,375,923.41 | 548,572,730.16 | 508,252,682.55 | 469,707,474.59 |
| 非流动负债: | | | | |
| 长期借款 | - | - | - | 22,145,000 |
| 租赁负债 | 7,174,678.7 | 2,527,379.62 | 3,903,550.51 | 1,404,239.01 |
| 递延收益 | 19,507,084.56 | 20,509,733.58 | 21,512,382.6 | 22,515,031.62 |
| 递延所得税负债 | 136,324,307.6 | 4,354,459.52 | 4,423,281.91 | 4,492,383.86 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 163,006,070.86 | 27,391,572.72 | 29,839,215.02 | 50,556,654.49 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 913,381,994.27 | 575,964,302.88 | 538,091,897.57 | 520,264,129.08 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 504,248,738 | 504,248,738 | 504,248,738 | 504,248,738 |
| 资本公积 | 4,062,997,016.14 | 4,062,997,016.14 | 4,062,997,016.14 | 4,062,997,016.14 |
| 其他综合收益 | 2,363,203.42 | - | - | - |
| 盈余公积 | 252,124,369 | 252,124,369 | 252,124,369 | 252,124,369 |
| 未分配利润 | 2,665,417,623.85 | 2,761,809,462.51 | 2,665,076,144.25 | 2,652,405,341.45 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 7,487,150,950.41 | 7,581,179,585.65 | 7,484,446,267.39 | 7,471,775,464.59 |
| 少数股东权益 | 611,824.31 | 803,570.18 | 807,576.02 | 810,877.21 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 7,487,762,774.72 | 7,581,983,155.83 | 7,485,253,843.41 | 7,472,586,341.8 |
| 负债和股东权益合计 | 8,401,144,768.99 | 8,157,947,458.71 | 8,023,345,740.98 | 7,992,850,470.88 |
| 公告日期 | 2025-03-19 | 2024-10-25 | 2024-08-24 | 2024-04-24 |
| 审计意见(境内) | 标准无保留意见 | | | |